Nektar Therapeutics (STU:ITH) Capex-to-Revenue : 0.03 (As of Sep. 2024)

Nektar Therapeutics Capex-to-Revenue Chart

Nektar Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Capex-to-Revenue		Get a 7-Day Free Trial					0.23	0.05	0.15	0.06	0.01

Nektar Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Capex-to-Revenue	Get a 7-Day Free Trial															-	0.01	0.01	0.01	0.03

Competitive Comparison of Nektar Therapeutics's Capex-to-Revenue

For the Biotechnology subindustry, Nektar Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Capex-to-Revenue falls into.

Nektar Therapeutics Capex-to-Revenue Calculation

Nektar Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Nektar Therapeutics's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics  (STU:ITH) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Nektar Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics Business Description